The U.S. Food and Drug Administration (FDA) has issued its final guidance detailing regulatory expectations for mobile applications and software that are used in conjunction with prescription drugs.

This guidance provides recommendations aimed at developers and healthcare providers focused on enhancing safety, managing risks, and conducting clinical evaluations of these digital tools in patient care.

By clarifying these expectations, the FDA aims to support the integration of software technologies that assist in the safe and effective use of prescription medications.

The final guidance underscores the importance of thorough evaluation and risk assessment to ensure these applications meet necessary standards in clinical settings.